Organon & Co Ordinary Shares OGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $13.49
- Day Range
- $13.49–13.53
- 52-Week Range
- $5.69–13.60
- Bid/Ask
- $13.48 / $13.53
- Shares Outstanding
- 262.61M
- Market Cap
- $3.55B
- Volume/Avg
- 2M / 7M
Key Statistics
- Price/Earnings (Normalized)
- 4.04
- Price/Sales
- 0.57
- Dividend Yield (Trailing)
- 0.59%
- Dividend Yield (Forward)
- 0.59%
- Total Yield
- 0.59%
Company Profile
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Value
- Total Number of Employees
- 10,000
- Website
- https://www.organon.com
Valuation
|
Metric
|
OGN
|
|---|---|
Price/Earnings (Normalized) | 4.04 |
Price/Book Value | 3.93 |
Price/Sales | 0.57 |
Price/Cash Flow | 3.80 |
Price/Earnings
OGN
Financial Strength
|
Metric
|
OGN
|
|---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.97 |
Interest Coverage | 2.09 |
Quick Ratio
OGN
Profitability
|
Metric
|
OGN
|
|---|---|
Return on Assets (Normalized) | 6.64% |
Return on Equity (Normalized) | 114.31% |
Return on Invested Capital (Normalized) | 13.25% |
Return on Assets
OGN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|@H^m!bC> | LOCK|<M! | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|<K^!K<r | LOCK|jw | $609B | |||
| AbbVie Inc
ABBV
| LOCK|kfW^%>T | LOCK|rwy | $450B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|B$M#&zZ | LOCK|!$% | $330B | |||
| Merck & Co Inc
MRK
| LOCK|DqJmtV^ | LOCK|Gg@ | $315B | |||
| Novartis AG ADR
NVS
| LOCK|zBvwbCv | LOCK|@R | $295B | |||
| AstraZeneca PLC
AZN
| LOCK|>QTG>%Z$ | LOCK|Rz | $263B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|dk?lxz< | LOCK|t< | $223B | |||
| Amgen Inc
AMGN
| LOCK|RcLVK!& | LOCK|VvF | $198B | |||
| Gilead Sciences Inc
GILD
| LOCK|TYk%^# | LOCK|@x | $167B |
United States